Joshua Kazam compensation by year
Allogene Therapeutics Summary Compensation Table · the one fiscal year held| Component | FY2018 |
|---|---|
| Salary | $0 |
| Bonus | $0 |
| Stock awards | $3,592,474 |
| Option awards | $0 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $0 |
| Total | $3,592,474 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Allogene Therapeutics, Inc. DEF 14A filed April 24, 2019, accession 0001193125-19-115774, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Allogene Therapeutics, Inc. filed document, accession 0001193125-19-115774. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2019.
Equity holdings
unvested awards at FY2018 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 1,028,951 | $27,709,650 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Allogene Therapeutics, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
8 Form 4 lines since the FY2018 proxy (filed April 24, 2019)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-18 | Exercise or conversion derivative | — | 47,700 | $0.00 | 0 |
| 2026-06-18 | Grant or award derivative | — | 95,400 | $0.00 | 95,400 |
| 2026-06-18 | Exercise or conversion | — | 47,700 | $0.00 | 398,463 |
| 2025-12-18 | Exercise or conversion | — | 47,700 | $0.00 | 350,763 |
| 2025-12-18 | Exercise or conversion derivative | — | 47,700 | $0.00 | 47,700 |
| 2025-06-18 | Grant or award derivative | — | 94,500 | $0.00 | 94,500 |
| 2024-06-05 | Grant or award derivative | — | 191,082 | $0.00 | 191,082 |
| 2023-06-13 | Grant or award derivative | — | 116,120 | $0.00 | 116,120 |
The 8 most recent of 8 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Allogene Therapeutics’s named executive officers, FY2018
as the company reported each| Named executive officer | Role | FY2018 total |
|---|---|---|
| David Chang | President and Chief Executive Officer | $12,848,537 |
| Joshua Kazam · this page | Former President | $3,592,474 |
| Eric Schmidt | Chief Financial Officer | $2,588,989 |
| Alison Moore | Chief Technical Officer | $1,836,614 |
Board service
Allogene Therapeutics board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $47,000 | $123,066 | $0 | $0 | $170,066 |
| FY2024 | $54,000 | $0 | $298,650 | — | $366,650 |
| FY2023 | $50,500 | $0 | $423,993 | $210,000 | $684,493 |
| FY2022 | $54,000 | $424,992 | $0 | $657,000 | $1,135,992 |
| FY2021 | $54,000 | $424,988 | $0 | $603,160 | $1,082,148 |
Each year as the company reported it in Allogene Therapeutics's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Allogene Therapeutics pays directors a $40,000 cash retainer and $300,000 in RSUs/Options. As stated in Allogene Therapeutics's FY2025 proxy.
Committees
International and Business Development Oversight
The full Allogene Therapeutics compensation record
free company briefThis page is one person within Allogene Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Allogene Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Allogene Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.